SEC Form 4 · accession 0001104659-26-097388
BioXcel Therapeutics, Inc. · BTAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Susan E. Atkins
Director
Period of report
Aug 12, 2026
Accepted (ET)
Aug 14, 2026 · 7:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001720893
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.06 | Aug 12, 2026 | A | 17,000 | A | — | Aug 12, 2036 | Common Stock | 17,000 | 17,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 33% of the underlying shares on the first anniversary of the grant date, and the remaining shares vest in two equal annual installments thereafter on the second and third anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through the relevant vesting dates.